In addition to this, Gleeson JP et al. analyzed 26 patients with FH-deficient RCC to assess the efficacy of combined treatment with vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR), and the study demonstrated that the objective response rate of this combination therapy was 44% [46]. Here, VEGFA is linked to renal cell carcinoma.